Tender Details

Country: USA
Summary: Prevent Cancer Preclinical Drug Development Program
UST Ref No: 73105509
Deadline: 28 Oct 2022
Financier: Self Financed
Purchaser Ownership: Government
Tender Value: Refer Document
Notice Type: Tender
Document Ref. No.:
Purchaser's Detail:
Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
Login to see details
Description:
Description
Pre-Solicitation Notice of Intent to Sole Source
PREVENT Cancer Preclinical Drug Development Program:
This is a sole source synopsis for the Indefinite Delivery Indefinite Quantity (IDIQ) contracts within the PREVENT Cancer Preclinical Drug Development Program, herein referred to as the PREVENT 2019 IDIQ Contracts. The current IDIQ consists of three pools, Preclinical Efficacy and Intermediate Endpoint Biomarker Pool (herein referred to as the Efficacy Pool), Toxicology and Pharmacology Testing Pool (herein referred to as the Tox/Pharm Pool), and Biopharmaceutical Product Development and Manufacturing Pool (herein referred to as the CGMP Pool). This announcement constitutes a synopsis for this requirement, is issued for notification purposes only and is not a request for competitive proposals.
The National Cancer Institute (NCI) plans to issue modifications to increase the shared programmatic ceilings on each of the PREVENT 2019 IDIQ Contracts to continue to advance the preclinical development of cancer-preventative interventions and intermediate biomarkers and to support/enable their clinical translation. This continued Efficacy work is accomplished by conducting preclinical animal studies for cancer preventive efficacy evaluation, employing detailed pharmacological and/or immunological studies, determining pharmacodynamic (PD) and/or immunodynamic (ID) effects of test agents, and correlating pharmacokinetic and/or immunologic biomarker profile(s) with the effectiveness of test agents. This continued Tox/Pharm work is accomplished through studies in genotoxicity testing, general toxicology in experimental animals, reproductive toxicology studies in rodents and rabbits and other specialized studies. This continued cGMP work is accomplished through product development planning and evaluation, analytical assay development and product characterization, process development and related activities and cGMP manufacture, related activities and do...
Documents:

If you are registered member, kindly login to view full details of this tender notice:

Prevent Cancer Preclinical Drug Development Program - USA Tender

The HEALTH AND HUMAN SERVICES, DEPARTMENT OF, a Government sector organization in USA, has announced a new tender for Prevent Cancer Preclinical Drug Development Program. This tender is published on USARFP under UST Ref No: 73105509 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2022-10-28.

The estimated tender value is Refer Document, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.